Invesco Galaxy Bitcoin ETF vs Medpace Holdings Inc — how do they compare? Invesco Galaxy Bitcoin ETF trades at $62.92, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BTCO | MEDP | |
|---|---|---|
Sector | Crypto-linked | Technology |
52-Week High | $125.14 | $620.59 |
52-Week Low | $58.40 | $393.42 |
Market Cap | — | $16.90B |
Enterprise Value | — | $16.52B |
Signals from Pluang's Aura AI — not financial advice
BTCO trades at $63.03, down 0.93% for the session. Technical indicators show a bullish trend with moving averages supporting upward momentum, while oscillators remain neutral. The stock faces resistance at $65 with support at $64. Recent financial data shows key valuation and profitability metrics are currently unavailable for analysis.
The stock's technical setup suggests potential for near-term upside if resistance levels are breached. However, the absence of fundamental financial metrics creates significant uncertainty about the company's underlying business performance and valuation. Investors face elevated risk due to limited visibility into financial health and operational metrics.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →